Abstract Development of new drugs is of high interest for the field of cardiac and
cardiovascular diseases, which are a dominant cause of death worldwide. Before being …

Although the clinical outcomes of cell therapy trials have not met initial expectations,
emerging evidence suggests that injury-mediated tissue damage might benefit from the …

Human iPSC-derived cardiomyocytes (hiPSC-CMs) have proven invaluable for cardiac
disease modeling and regeneration. Challenges with quality, inter-batch consistency …

Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes (CMs)(iPSC-CMs) are
a promising cell source for myocardial regeneration, disease modeling and drug …

Despite significant efforts in the study of cardiovascular diseases (CVDs), they persist as the
leading cause of mortality worldwide. Considerable research into human pluripotent stem …

Cardiovascular diseases (CVDs) are the leading causes of mortality globally that demand
the application of tissue engineering strategies to repair damaged tissues. Conventional …

The lack of a scalable and robust source of well-differentiated human atrial myocytes
constrains the development of in vitro models of atrial fibrillation (AF). Here we show that …

Cardiovascular diseases are one of the leading causes of death globally. Among various
cardiovascular diseases, myocardial infarction is an important one. Compared with …

During the past decades, stem cell‐based therapy has acquired a promising role in
regenerative medicine. The application of novel cell therapeutics for the treatment of …

Tissue engineering has paved the way for the development of artificial human cardiac
muscle patches (hCMPs) and cardiac tissue analogs, especially for treating Myocardial …